FDA Tweaks Drug Codes for Easier Barcode Scans
Published Date: 3/5/2026
Rule
Summary
The FDA is updating the National Drug Code (NDC) to a clear, 12-digit format with three parts to make drug labeling easier to read and track. They’re also allowing new types of barcodes on drug packages that meet these rules. This change affects drug makers and sellers and kicks in on March 7, 2033, giving everyone plenty of time to get ready without extra costs.
Analyzed Economic Effects
8 provisions identified: 6 benefits, 2 costs, 0 mixed.
All FDA NDCs Must Be 12 Digits
FDA requires every FDA-assigned National Drug Code (NDC) to be 12 digits in a 6-4-2 format (6-digit labeler, 4-digit product, 2-digit package). This requirement takes effect March 7, 2033 and applies to existing 10-digit NDCs, which must be converted to the 12-digit format.
Industry Cost Estimate Provided
FDA estimates annualized industry costs to convert to the uniform 12-digit NDC format at about $14.64 million (range $7.64M to $22.79M) using a 7% discount rate, and about $14.90 million (range $7.79M to $23.18M) using a 3% discount rate, over a 10-year horizon.
Standardization Aims to Reduce Medication Errors
FDA says a single, uniform 12-digit NDC format should reduce errors from converting between multiple NDC formats and lower the need for extra quality control by payors and prescribers. FDA also notes the rule should help avoid potential public-health risks from medication confusion.
7-Year Delay Before Rule Starts
FDA set the rule's effective date 7 years after publication, so the 12-digit NDC requirement starts on March 7, 2033. FDA states it will use that 7-year period to engage with and help industries prepare for the change.
3-Year Post-Effective Label Transition
After the March 7, 2033 effective date, FDA allows a 3-year transition period during which it does not intend to object to continued use of pre-existing 10-digit NDCs on drug labeling for products remaining in interstate commerce. During this transition, firms should make systems that can handle both 10-digit and 12-digit formats.
Barcode Options Expanded for Labels
FDA will allow either linear or nonlinear barcodes on drug labels as long as the barcode format conforms to the rule's standards and is recognized by FDA. This gives manufacturers flexibility in choosing barcodes that meet the new requirements.
FDA Will Publish 10-to-12 Digit Mapping
FDA intends to publish a database that maps each existing 10-digit NDC to its corresponding 12-digit NDC and will keep that mapping available at least until the end of the transition period. This mapping aims to reduce conversion errors during implementation.
Converted NDCs Aren't 'New' NDCs
FDA states converting a pre-effective-date 10-digit NDC into the 12-digit format is a ministerial administrative change and is not considered assignment of a "new" NDC for registration, listing, or user-fee purposes. A drug gets a truly new NDC only if FDA assigns a new NDC after the effective date because of a product change described in regulation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04365 — National Standards for Traffic Control Devices; the Manual on Uniform Traffic Control Devices for Streets and Highways; Revision
The Federal Highway Administration just updated the national rulebook for traffic signs and signals, called the MUTCD, fixing small errors and making things clearer for everyone on public roads. This update affects all drivers, bikers, and road workers by helping keep roads safer and easier to navigate. The new rules kick in on March 5, 2026, with no big costs, just smoother, smarter traffic control everywhere.
Next: 2026-04373 — Rules Regarding Delegation of Authority; Correction
The Federal Reserve fixed and updated its rules about who can make certain decisions on its behalf. This change adds some previously approved delegations and corrects small errors to keep things running smoothly. It affects Board members, staff, and Reserve Banks and takes effect immediately on March 5, 2026, with no new costs involved.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in